Navigation Links
The interplay of genes, diet and heart disease

FAs as modulators of genetic effects in lipid metabolism," write the authors. They go on to explain that "a more complete understanding of these factors and a thoughtful use of this information should help in the identification of vulnerable populations who will benefit from more personalized dietary recommendations."

A second study published by Ordovas, Lai, and colleagues in the Journal of Lipid Research also studied variants of the APOA5 gene in participants in the Framingham Heart Study to determine if the gene is related to atherosclerosis. The authors, including corresponding author Christopher O'Donnell of the National Heart, Lung, and Blood Institute's Framingham Heart Study, and first author Roberto Elosua, a former Fulbright-Generalitat de Catalu?a fellow who works with Ordovas, found that while most variants of the APOA5 gene were not associated with carotid intimal medial thickness (IMT), a surrogate measure of atherosclerosis burden, particular gene variants were "significantly associated with carotid IMT in obese participants."

Carriers of the particular gene variants who were obese expressed the effects of the gene variant differently than carriers who were not obese, showing a greater build-up of plaque in the heart. This was true for participants who were obese regardless of fat and cholesterol levels in the blood, age, gender, smoking or diabetes status, weight-for-height and blood pressure, all factors which are thought to influence risk of heart disease. Lai notes that "although obesity is a known contributing factor to heart disease, the association was strengthened in carriers of the rare APOA5 variant who were obese."

"It may be more important for some people to make preventive dietary and lifestyle changes than others, depending on their genetic makeup," says Ordovas. "The 'bad' genotype, in this study, doesn't seem to be that bad unless it's triggered by obesity," he concludes. "The observations, while strong,
'"/>




Page: 1 2 3 4

Related medicine news :

1. Starvation in pregnant women can cause heart disease to their children
2. Individuals with sleep related breathing disorders more prone to heart disease
3. And now they say infections can cause heart disease!!!!
4. And now they say infections can cause heart disease!!!!
5. Award for TTK Chitra heart valve prosthesis
6. Eat greens to have a ever green heart
7. Asthma! A new warning for heart disease
8. Protein in urine foresees heart disease
9. One...just one cigarette can spoil the heart function.
10. Risk of heart disease begins in teens
11. Beer vitamin protects heart
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: The interplay genes diet and heart disease

(Date:5/15/2008)...irstCall/ -- Genesis,Pharmaceuticals Enterprises, ..."Company"), a U.S. pharmaceutical company with its...China, today announced its financial results,for t...rd quarter of its,fiscal year ended June 30, 2008.....S. Securities Exchange Commission that is availab...
(Date:5/15/2008)...irstCall/ -- Alexza,Pharmaceuticals, Inc. (Nasdaq:...joined the company as Vice President, Quality. He ...execution of quality program,strategies for Alexza...ical,product candidates. Mr. Parra was most recent..., Inc. in Palo Alto, California, where he was empl...
(Date:5/15/2008)...nsive Healthcare Plans, Long Term Care Will C...KLAND, Wash., May 15 /PRNewswire-USNewswire/ -- Wi... "Probably," says Cameron Truesdell,CEO of one of...rance,agencies, LTC Financial Partners LLC. Will t...Cain,s -- cover all healthcare needs? "Absolutely,...
(Date:5/15/2008)...-- Congresswoman Lois Capps,(D-CA) and the staff o...d a,briefing for key staff members of the House, o...s., WHEN: Monday, May 19th at 2 PM, WHERE: Ray...cussants includes Mary Hesdorffer, a nurse practit... Applied Research Foundation, who,specializes in a...
Breaking Medicine News(10 mins):Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 2Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 3Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 4Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 5Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 6Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 7Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 8Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 9Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 10Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 11Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 12Health News:Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality 2Health News:Don't Wait for the Election to Plan Your Long-Term Healthcare, Insurance Leader Advises 2
... people are affected by polio and as of now 15 peo...ct a three-day mass vaccination campaign to fight ...ibian dollars, said Kalumbi Shangula, permanent se...t 96 people have been affected by the outbreak in ...
...ere are now insisting on HIV tests ahead of marria...d an increase in the number of HIV tests, particul...me changed) got an HIV test done last year. "I w...her. But her parents thought I was a flirt," said ...
...esented at the 22nd annual conference of the Europ...n Prague, has found that many parents //are comfor...o fertilization. However the Iowa researchers fou...he risks of the process. "Along with many infertil...
...y by researchers from Duke University Medical Cent... blood transfusion into patient //who has undergon...se with raised death risks. Use of older blood al...for kidney problems,acute respiratory distress and...
Other Medicine News:Health News:Repeated Heart Surgery with Older Blood Transfusion Pack More Death Risk 2Health News:Repeated Heart Surgery with Older Blood Transfusion Pack More Death Risk 3
(Date:5/14/2008)...for cervical cancer prevention, GRAZ, Austria, Ma...tended follow-up study show that GlaxoSmithKline (...RVARIX(R) generates sustained high levels of,neutr...vical cancer-causing,human papillomavirus types fo... sustained neutralizing antibody levels observed a...
(Date:5/14/2008).../ -- Results of the PRoFESS(R),(Prevention Regimen... the,world,s largest clinical research study for s... at the XVII European Stroke Conference in Nice,F...for Aggrenox(R) and,clopidogrel were similar (9.0%...). The study did not meet its primary endpoint of ...
(Date:5/14/2008)...ocate to lead expansion of Cytel,s adapt...BRIDGE, Mass., May 14 /- Cytel Inc., ...es and specialized statistical software,today ann...resident,Adaptive Trials., Judith Quinlan brings...e Cytel team. Prior to joining Cytel Judith spent ...
(Date:5/14/2008)...irstCall/ -- Kosan Biosciences,Incorporated (Nasda...be,presented on tanespimycin, the company,s lead H...n with Herceptin(R) in patients with HER2-positive...ing of the American,Society of Clinical Oncology (... May 31 through June 3, 2008., Abstract 1027, tit...
Breaking Medicine Technology:CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 2CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 3CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 4CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 5CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 6PRoFESS(R) Results Announced at XVII European Stroke Conference 2PRoFESS(R) Results Announced at XVII European Stroke Conference 3PRoFESS(R) Results Announced at XVII European Stroke Conference 4PRoFESS(R) Results Announced at XVII European Stroke Conference 5Judith Quinlan Joins Cytel as Vice President, Adaptive Trials 2Kosan Announces Data Presentations at ASCO 2008 Annual Meeting 2Kosan Announces Data Presentations at ASCO 2008 Annual Meeting 3Winter Brings Pet Hazards 7495 1Winter Brings Pet Hazards 7495 2University Hospital of Bordeaux Officially Opens New Electrophysiology Lab 7490 1University Hospital of Bordeaux Officially Opens New Electrophysiology Lab 7490 2University Hospital of Bordeaux Officially Opens New Electrophysiology Lab 7490 3K State researchers findings on E coli 1444 1K State researchers findings on E coli 1444 2Studies review smoking among college freshmen and tobacco use by adolescents with ADHD 7487 1Studies review smoking among college freshmen and tobacco use by adolescents with ADHD 7487 2Studies review smoking among college freshmen and tobacco use by adolescents with ADHD 7487 3Studies review smoking among college freshmen and tobacco use by adolescents with ADHD 7487 4Studies review smoking among college freshmen and tobacco use by adolescents with ADHD 7487 5
... - Inovio Biomedical,Corporation (AMEX:INO), focus...r cancers and infectious diseases and a novel,alte...ounced today,that interim clinical trial results d...ed by Inovio,s electroporation technology was,safe...esulted in,significant objective tumor responses i...
..., 2007 - Cytos,Biotechnology AG (SWX:CYTN) reporte...blind combined phase I/IIa study with,CYT007-TNFQb...soriasis and other inflammatory conditions. The pr... and included 48 patients,suffering from moderate ... study, the safety and tolerability of ascending d...
Other Medicine Technology:Inovio Biomedical's DNA Delivery Technology Shows Safety and,Enhances Gene Expression & Tumor Responses in Interim Melanoma,Clinical Study Results 2Inovio Biomedical's DNA Delivery Technology Shows Safety and,Enhances Gene Expression & Tumor Responses in Interim Melanoma,Clinical Study Results 3Inovio Biomedical's DNA Delivery Technology Shows Safety and,Enhances Gene Expression & Tumor Responses in Interim Melanoma,Clinical Study Results 4Inovio Biomedical's DNA Delivery Technology Shows Safety and,Enhances Gene Expression & Tumor Responses in Interim Melanoma,Clinical Study Results 5Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for,the Treatment of Psoriasis 2Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for,the Treatment of Psoriasis 3Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for,the Treatment of Psoriasis 4
...e path that allows users to take full advantage of...ine two units offers fully programmable paired pul...The ability to change pulse intervals and to contr...00 allows for sub- and supra-threshold conditionin...
...CP) is a surgical approach to glaucoma management ... application. The ciliary body (which produces aqu...terior or posterior segment, through the endoscope...ccurately identified utilizing endoscopy. This all...
...CP) is a surgical approach to glaucoma management ... application. The ciliary body (which produces aqu...terior or posterior segment, through the endoscope...ccurately identified utilizing endoscopy. This all...
...CP) is a surgical approach to glaucoma management ... application. The ciliary body (which produces aqu...terior or posterior segment, through the endoscope...ccurately identified utilizing endoscopy. This all...
Medicine Products: